<DOC>
	<DOCNO>NCT01391546</DOCNO>
	<brief_summary>PRIMARY OBJECTIVES Two co-primary objective : - To demonstrate ZOSTAVAX administer intramuscular route ( IM ) non-inferior ZOSTAVAX administer subcutaneous route ( SC ) - To demonstrate ZOSTAVAX administer IM route induces acceptable fold-rise varicella zoster virus ( VZV ) antibody titres pre 4-week post-vaccination SECONDARY OBJECTIVES Immunogenicity objectives - To evaluate immunogenicity measure VZV antibody titres 4 week follow ZOSTAVAX administer IM SC route - To evaluate immune response measure second assay , VZV Interferon gamma Enzyme-linked immunospot ( ELISPOT ) 4 week follow ZOSTAVAX administer IM SC route Safety objective - To describe safety profile ZOSTAVAX administer IM SC route</brief_summary>
	<brief_title>Immunogenicity Safety Study ZOSTAVAX Administered Intramuscular Subcutaneous Route Subjects Aged From 50 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Adults age &gt; =50 year Varicella historypositive residence &gt; 30 year country endemic VZV infection Febrile illness History hypersensitivity anaphylactoid reaction vaccine component Prior herpes zoster episode clinically diagnose exposure varicella herpes zoster within 4 week prior vaccination Prior receipt varicella zoster vaccine Active untreated tuberculosis Thrombocytopenia , coagulation disorder contraindicate intramuscular injection Receipt medication / vaccine may interfere study assessment Known suspect immune dysfunction User recreational / illicit drug subject alcohol abuse dependence within last year Any condition might interfere interpretation study ,</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>